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sixteen pixellated LYSO crystals, coupled to multi-anode 
PhotoMultiplier, provides the particle energy measurement. 
The front-end electronics is composed of 4096 channels, and 
the read-out is performed by 128 ASICs (BASIC32_ADC) 
specifically designed for SiPMs read-out application [1], while 
trigger system and data acquisition are implemented with a 
system of 21 FPGAs.  
The detector design and optimization of the detector have 
been performed using Monte Carlo (MC) simulations based on 
the results of experimental measurements ([2], [3]). The DP 
hardware features of DP will be reviewed. The expected 
performance, as resulting from the MC, will be discussed in 
the clinical application framework. 
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We present an isocentric, carbon/proton superconducting 
and permanent magnet proton gantries, respectively, with a 
fixed magnetic field but very large momentum acceptance. 
During a treatment it is possible to do longitudinal and 
transverse spot scanning for the whole energy range 
required. The size and cost are dramatically reduced; for 
example compared to the weight of the Heidelberg 630 tons 
the weight is estimated to be about one tons. The proton 
gantry is of a size of the present PSI gantry, but it is made of 
small permanent Halbach magnets. It can transport very 
precisely the proton beam within a 30-250 MeV kinetic 
energy range, under the permanent magnetic field, with 
variation of the scanning magnets only with an infinite S.A.D.  
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As opposed to surgical disciplines, radiation oncology relies 
on non-invasive imaging of the target volume (tumor, lymph 
nodes or metastases). Apart from anatomical imaging for 
target volume delineation (e.g., CT, MRI), functional imaging 
(e.g., PET, functional CT and MRI) is increasingly being 
integrated in modern radiotherapy techniques. Functional 
imaging is used prior to therapy for guidance, dose-escalation 
strategies and treatment selection, but also early during 
irradiation for response monitoring and consequently 
treatment adaptation. Moreover, functional imaging is 
incorporated in the radiotherapy chain for identification of 
patients at increased risk of normal tissue complications 
(e.g., SPECT and CT for prediction of radiation pneumonitis). 
This presentation will present the current status of functional 
imaging for radiation oncology prior to and during treatment, 
both for the target volume and normal tissues. 
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As compared to photon beams, charged particle therapy such 
as both proton beam therapy (PBT) and carbon-ion 
radiotherapy (CIRT) offers improved dose distribution, 
localizing sufficient dose within a target volume while 
minimizing the dose to the surrounding normal tissues. In 
addition, carbon-ions being heavier than protons provide a 
higher radiobiological effectiveness (RBE), which increases 
with depth reaching the maximum at the end of the beam's 
range. This theoretically is an ideal property from the 
standpoint of cancer radiotherapy.  
In Japan, PBT and CIRT were both initiated at NIRS in 1979 
and 1983, respectively. Since then, various types of tumors 
have been prospectively treated. As of December 2015, there 
are a total of 13 charged particle therapy facilities in 
operation including 9 for PBT and 4 for CIRT.  Several other 
facilities are under construction or being planned for either 
PBT or CIRT. In 2003, we established JCPT (Japan Clinical 
Study Group of Particle Therapy) for the purpose of changing 
information and improving therapeutic techniques for 
charged particle therapy, as well as collecting clinical data 
from existing facilities in Japan. According to the survey of 
JCPT, a total of 30,850 patients were treated in Japan from 
1979 to 2014, including 17,858 patients (58%) with PBT and 
12,922 patients (42%) with CIRT. Male/female was 73%/27%. 
The age of the patients ranging <51, 51-60, 61-70, 71-80, >80 
was 12%, 17%, 34%, 29%, and 8%, respectively. As with the 
tumor types, the major tumors for PBT were prostate (30%), 
liver (19%), H&N (13%), lung (12%), GI (6%) and pancreas (4%), 
and those for CIRT were prostate (24%), H&N (14%), B&S 
(11%), lung (11%), liver (10%) and rectum/pancreas (5% 
each).  
Among 4 facilities for CIRT, the largest numbers of patients 
were treated at NIRS, starting CIRT in 1994 using HIMAC 
(Heavy-ion medical accelerator in Chiba). More than 9,000 
patients have been so far treated based on > 70 protocols, by 
which the benefit of CIRT over other modalities has been 
demonstrated in locally, advanced tumors and non-squamous 
cell types of tumors. Based on their unique biophysical 
characteristics, a significant reduction in overall time and 
fraction has been achieved with minor toxicities. This 
included a single-fraction RT for early-stage NSCLC, one or 
two-fraction RT for liver cancer and 12-fraction RT for 
prostate cancer. Even for other tumors, CIRT with 16 or 
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smaller fractions have been safely performed. This means 
that the facility can be operated more efficiently in CIRT, 
permitting treatment for a larger number of patients than is 
possible with other modalities over the same period of time. 
In 2010, a new treatment facility with three rooms was 
completed with the beam lines being extended from the 
existing accelerators, in which CIRT with a pencil beam 
scanning became available. Recently, we have successfully 
begun treatment of moving organs using respiratory-gated 
irradiation with a pencil beam scanning.  At the new facility 
a compact rotating gantry was constructed with its 
commissioning to be finished in the spring of 2016.  
In order to exchange information and perform a prospective 
study for CIRT, we have recently established J-CROS (Japan 
Carbon-ion Radiation Oncology Study Group). Under the 
framework of J-CROS, we will conduct multi-institutional 
studies on such tumors as head and neck tumors, NSCLC 
(mainly T2 tumors), hepatoma, pancreas cancer, post-
operative recurrence of rectal cancer, and bone & soft tissue 
sarcoma. These tumors are chosen based on the recognition 
that therapeutic techniques have not yet been fully 
established and treatment outcome should be further 
improved, as well as that reproducibility of NIRS clinical 
results should be evaluated by other groups. The J-CROS 
study will also include the study producing benchmark results 
in selected tumors, as well as a randomized study comparing 
CIRT with PBT or photon therapy.  
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Purpose: The aim of the present Monte Carlo study is to 
evaluate the variation of energy deposition in healthy tissues 
in the human eye which is irradiated by brachytherapy 
sources in comparison with the resultant dose increase in the 
gold nanoparticle (GNP)-loaded choroidal melanoma.  
Material and method: The effects of these nanoparticles on 
normal tissues are compared between 103 Pd and 125I as two 
ophthalmic brachytherapy sources. Dose distribution in the 
tumor and healthy tissues has been taken into account for 
both mentioned brachytherapy sources. Also, in certain 
points of the eye, the ratio of the absorbed dose by the 
normal tissue in the presence of GNPs to the absorbed dose 
by the same point in the absence of GNPs has been 
calculated. In addition, differences of  the absorbed dose in 
the tumor observed in the comparison of simple water 
phantom and actual simulated human eye in presence of 
GNPs are also a matter of interest that have been considered 
in the present work.  
Result and conclusion: The difference between the eye globe 
and the water phantom is more obvious for 125I than that of 
the 103 Pd when the ophthalmic dosimetry is done in the 
presence of GNPs. Whenever these nanoparticles are utilized 
in enhancing the absorbed dose by the tumor, the use of 125I 
brachytherapy source will greatly amplify the amount of dose 
enhancement factor (DEF) in the tumor site without inflicting 
much damage to healthy organs, when compared to the 103 Pd 
source. Furthermore in Monte-Carlo studies of eye 
brachytherapy, more precise definition of the eye phantom 
instead of a water phantom will become increasingly 
important when we use 125I as opposed to when 103 Pd is 
considered. 
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Purpose: The emphasis of the present work is to compare the 
effects of gold nanoparticles (AuNPs) on healthy human 
ocular tissues in ophthalmic brachytherapy dosimetry, 
between water and eye phantoms by utilization of the two 
most noteworthy Monte-Carlo codes of GEANT4 and MCNP5. 
Material and method: The intended study was based upon a 
simulated model of the human eye consisting different parts 
such as Lens, Cornea, retina, Choroid, Sclera, skull bone, 
Anterior Chamber and a melanoma tumor which was latticed 
to house AuNPs required for the dosimetry comparisons of 
two uniquely defined radionuclides of 125I and 103Pd. The 
effects of the presence of AuNPs on the absorbed dose by the 
tumor have been taken into account using both Monte-Carlo 
codes mentioned above; furthermore, the aberrations in dose 
calculations of the simple eye phantom and the realistic eye 
model were also an element of consideration. The 
importance of such evaluations on various compositions that 
are most common in Monte Carlo studies could prove to be 
rewarding, especially in presence of external anomalies such 
as AuNPs.  
Result and Conclusion: With respect to the numerous 
distinctions between codes themselves, it is always fruitful to 
compare multiple of these programs with one another; 
hence, a rigorous inspection of the results has been 
executed, and dissimilarities have been highlighted for better 
understanding of the advantages and deficiencies of both 
codes. All in all, it is best stated that interdisciplinary 
methods of combining diverse therapeutic applications have 
gained much ground in our current era, and serve to 
significantly increase efficiency of cures worldwide.  
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